Jake Ellison, UW News

When a vaccine to fight COVID-19 has been approved by the FDA for distribution, it’s unlikely that at first there will be enough doses for everyone. Consequently, the United States will need an equitable and effective plan for who gets those first doses, how they get them and who’s next.

Just as important, that plan — like the vaccine itself — has to be trusted and accepted by the general public.

On October 1, the International Training and Education Center for Health (I-TECH) celebrated the launch of the local and independent Botswana Training and Education Center for Health (B-TECH) and Caribbean Training and Education Center for Health (C-TECH).

To celebrate the UW School of Public Health’s 50 years of impact, the School is recognizing 50 alumni from around the world who have a demonstrated record of distinguished service and achievement across public health disciplines and settings. These 50 Changemakers of Public Health are leaders, trailblazers, educators, innovators, influencers and health equity heroes that represent just a slice of the School’s community of more than 10,000 alumni worldwide who are addressing some of the most pressing population health issues of our time.

UW Medicine, Fred Hutch scientists will jointly test whether the monoclonal drug can prevent infection among people exposed to COVID-19.

Researchers at UW Medicine and the Fred Hutchinson Cancer Research Center are jointly testing monoclonal antibodies created by Regeneron Pharmaceuticals to prevent COVID-19, and are starting to recruit patients.